Luca Giordano

Dr. Luca Giordano

University of Padua, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Food Microbiology
Verified
Journal Article
Closed access
CGCarmela Gerardi
Carmela Gerardi
MTMariana Tristezza
Mariana Tristezza
LGLuca Giordano
Luca Giordano
PRPatrizia Rampino
Patrizia Rampino
CPCarla Perrotta
Carla Perrotta
Francesco GriecoFrancesco Grieco
Francesco Grieco

DTDavide Di Tonno
Davide Di Tonno
CPCaterina Perlin
Caterina Perlin
ALAnna Chiara Loiacono
Anna Chiara Loiacono
LGLuca Giordano
Luca Giordano
LMLaura Martena
Laura Martena
AAAlberto Argentiero
Alberto Argentiero
Background: Phase 1 clinical trials represent a critical phase of drug development because new candidate therapeutic agents are tested for the first time on humans. Therefore, international guidelines and local laws have been released to mitigate and control possible risks for human health in agreement with the declaration of Helsinki and the international Good Clinical Practice principles. Despite numerous scientific works characterizing the registered clinical trials on ClinicalTrials.gov, the main features and trends of registered phase 1 clinical trials in Europe have not been investigated. This study is aimed at assessing the features and the temporal trend of distribution of phase 1 clinical studies, carried out in the five largest European countries over a ten-year period (2012–2021), and to evaluate the impact of the Italian regulatory framework on the activation of such studies. Methods: The main data and characteristics of phase 1 clinical studies registered on the ClinicalTrials.gov database for France, Germany, Italy, Spain and the United Kingdom have been investigated and subsequently compared. The above-mentioned countries were selected based on similarities in terms of demographic and Gross Domestic Product (GDP) data available on official government websites. (3) Results: A total number of 6878 phase 1 clinical trials were registered for the five selected countries in the ClinicalTrials.gov database during the ten years analyzed; the studies were predominantly randomized (39.33%) and for-profit (76.64%). The most represented area of investigations was oncology (52.15%), followed by hematology (24.99%) and immunology (12.04%). The variability observed between the analyzed countries showed that the UK, Germany and France presented the highest reduction in the number of phase 1 clinical trials, while for Spain and Italy, a stable/increased trend was observed, although with a lower number of trials registered on the ClinicalTrials.gov database. (4) Conclusions: Italy displayed the lowest number of registered phase 1 clinical trials, even though it showed a stable trend over the years. In this regard, the Italian regulatory framework must urgently be adapted to that of other European countries (Spain has been the first country to implement the new Regulation (EU) No 536/2014) and streamline the process of clinical trial application to increase the attractiveness of the country. Moreover, nonprofit phase 1 clinical trials (which represent 19.81% of the total number of phase 1 clinical trials registered in Italy vs. 80.19% of profit phase 1 clinical studies) should be promoted and supported by the institutions, even from a financial point of view, to allow independent researchers to develop new therapeutic drugs.

1 January 2021 in Journal of Energy Markets
Verified
Journal Article
Open access
PDF file
LGLuca Giordano
Luca Giordano
DMDaniela Morale
Daniela Morale
This paper proposes a new model for the description and forecast of gross prices of electricity in the liberalized Italian energy market via an additive two

20 July 2022 in Applied Sciences
Verified
Journal Article
Open access
PDF file
LGLuca Giordano
Luca Giordano
AFAndrea Francavilla
Andrea Francavilla
Corrado LaneraCorrado Lanera
Corrado Lanera
SUSara Urru
Sara Urru
Paola BerchiallaPaola Berchialla
Paola Berchialla
IBIleana Baldi
Ileana Baldi
Patients are the most important actors in clinical research. Therefore, patient preference information (PPI) could support the decision-making process, being indisputable for research value, quality, and integrity. However, there is a lack of clear guidance or consensus on the search for preference studies. In this blueprint, an openly available and regularly updated patient preference management system for an integrated database (PPMSDB) that contains the minimal set of data sufficient to provide detailed information for each study (the so-called evidence tables in systematic reviews) and a high-level overview of the findings of a review (summary tables) is described. These tables could help determine which studies, if any, are eligible for quantitative synthesis. Finally, a web platform would provide a graphical and user-friendly interface. On the other hand, a set of APIs (application programming interfaces) would also be developed and provided. The PPMSDB, aims to collect preference measures, characteristics, and meta-data, and allow researchers to obtain a quick overview of a research field, use the latest evidence, and identify research gaps. In conjunction with proper statistical analysis of quantitative preference measures, these aspects can facilitate formal evidence-based decisions and adequate consideration when conducting a structured decision-making process. Our objective is to outline the conceptual infrastructure necessary to build and maintain a successful network that can monitor the currentness and validity of evidence.